

## KidneyX Focus Areas + Potential Products

### **NEXT-GEN KIDNEY REPLACEMENT**

Wearable or implantable dialyzers, bio-artificial kidneys, xenotransplant technology, etc.

### **MEDICATIONS**

Drugs specifically designed to prevent, treat, and slow progression of kidney diseases, as well as encompass the needs of kidney transplant patients

### **DEVICES**

Devices that support the management and treatment of kidney diseases that are not dialyzers (such as vascular access technologies, etc.)

### **DIAGNOSTICS**

Point-of-care or at home testing kits, real time kidney monitoring, etc.

### **PATIENT-CENTERED TOOLS**

Tools designed to identify and track disease, applications to empower patients to manage kidney diseases (e.g., apps)



**Transforming the Development of Kidney Care**

40 million Americans live with kidney diseases.  
More than 700,000 Americans have kidney failure.

**There is no cure.**



**For more information, please contact  
[kidneyx@asn-online.org](mailto:kidneyx@asn-online.org).**

## KidneyX is a public-private partnership to:

- Seed, incentivize, and accelerate breakthroughs in kidney care
- Provide better coordination among HHS, NIH, FDA, and CMS to clear a path towards commercialization
- Create a sense of urgency to bring breakthrough therapies to patients, including fostering multidisciplinary collaboration and engaging the investment community

### What KidneyX Does

- ✓ Incentivizes the accelerated development and commercialization of disruptive solutions
- ✓ Bridges the gap between research and market-ready products
- ✓ Provides merit-based, non-dilutive funding to promising innovators through a series of prize competitions

## KidneyX Features

	<p><b>Public-Private Partnership</b></p> <ul style="list-style-type: none"> <li>• Matching funds from public and private sponsors</li> <li>• Access to a community of investors, business and manufacturing experts, scientists, engineers, patients, payers, and other stakeholders</li> </ul>
	<p><b>Support for Innovative Approaches</b></p> <ul style="list-style-type: none"> <li>• Non-dilutive funding to promising innovators</li> </ul>
	<p><b>Reimagining How HHS Advances Clinical Trials</b></p> <ul style="list-style-type: none"> <li>• Clinical trial co-design with NIH, FDA, and CMS to expedite trials</li> <li>• Engaging CMS early to optimize trial design from coverage standpoint</li> </ul>

### Why KidneyX is Needed

- ✓ Medicare annually spends \$34 billion treating kidney failure
- ✓ Kidney failure is still managed with dialysis, a therapy invented 50 years ago
- ✓ Lack of private investment and venture capital, misaligned public incentives, and a complex regulatory process inhibits innovative ideas from becoming commercially available therapies

### Why KidneyX is the Solution

- ✓ **Achievable:** Similar public-private accelerators have shown immense success, including CARB-X
- ✓ **Comprehensive:** KidneyX will spur innovation across kidney care by supporting the development of improved diagnostics and therapeutics, patient-centered tools to manage kidney diseases, and next-generation dialysis

### How You Can Help

- ✓ **Thank HHS:** Sign letter commending Secretary Azar for HHS commitment to KidneyX
- ✓ **Follow KidneyX:** Subscribe to updates at [www.KidneyX.org](http://www.KidneyX.org) or follow @Kidney\_X on Twitter